Aktis Oncology (NASDAQ:AKTS) Stock Price Down 6.6% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS) fell 6.6% during trading on Monday . The company traded as low as $25.91 and last traded at $26.0390. 62,182 shares traded hands during trading, a decline of 82% from the average session volume of 344,839 shares. The stock had previously closed at $27.88.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AKTS. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. William Blair initiated coverage on Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. HC Wainwright increased their price target on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Finally, Raymond James Financial began coverage on Aktis Oncology in a report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Aktis Oncology Price Performance

The firm has a fifty day moving average price of $22.75. The company has a market cap of $1.35 billion and a price-to-earnings ratio of -66.66.

Aktis Oncology (NASDAQ:AKTS) last released its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million for the quarter. As a group, research analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.